Unfortunately, misinformation about these medications has also taken the Internet by storm
Shah says he would caution people with type 1 who are not overweight to avoid taking a GLP-1 drug, since retrospective studies have found that this group tends to have more gastrointestinal side effects, which may lead them to stop using the drug
First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists : A cost-effectiveness study
Heres the month-by-month breakdown based on aggregate data from 338 Phase 2 trial participants: This timeline is remarkably consistent across patients
doi: 10.1186/s13098-024-01337-5
In addition, GLP-1R reduces gluconeogenesis by delaying gastric emptying and decreasing appetite, which also contributes to glycemic control (Xie et al., 2022)